Synthego Wins Stay of Patent Suit on Agilent Genome-Editing Tech

Agilent Technologies Inc.’s bid to block sales of Synthego Corp.’s genome-editing products for the duration of a lawsuit over two Agilent patents won’t be resolved until a patent tribunal completes reviews of their validity, as a California federal judge granted Synthego’s bid to pause the case.

Judge Edward J. Davila granted Synthego’s stay request while the Patent Trial and Appeal Board considers whether the patents should have been issued, according to an opinion issued Tuesday in the US District Court for the Northern District of California.

Davila said he agreed to the stay because the case is in its ...